Article
A Genome-Wide Association Study Identifying SVEP1 Variant as a Predictor of Response to Tolvaptan for Cirrhotic Ascites
2021-04-28
Abstract excerpt
<title>Abstract</title> <p>Background and Aims: Tolvaptan, an orally active vasopressin V2-receptor antagonist, has been used for patients with difficult-to-treat ascites in Japan. In this study, we conducted a genome-wide association study (GWAS) in the Japanese population to identify genetic variants associated with tolvaptan’s efficacy for patients with hepatic ascites. <h4>Methods:</h4> From 2014 through 2018...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 813d2222-fea3-55e9-93c3-2e0b7e586ae8
- DOI
- 10.21203/rs.3.rs-388508/v1
